Helio Health and its commercial partner Fulgent Genetics have commercially launched a new liquid biopsy test, HelioLiver, for early liver cancer detection.
The multi-analyte blood test combines cell-free DNA (cfDNA) methylation patterns and serum protein markers.
It helps in the detection of hepatocellular carcinoma (HCC), the most common liver cancer form, in the earliest stages.
The process involves a simple blood draw and can be conducted during a routine check-up. This eliminates the need to schedule any additional appointments.
The new blood-based test provides an accurate and quick method to regularly monitor people who are at risk of developing the disease.
Fulgent Genetics stated that patients at risk of developing liver cancer are currently advised to undergo ultrasound screening every six months, in line with the guidelines of the American Association for the Study of Liver Diseases (AASLD).
Fulgent Genetics chief commercial officer Brandon Perthuis said: “Through our partnership with Helio, our joint priority is to bring HelioLiver to providers and patients in a seamless manner.
“Leveraging our extensive commercial infrastructure, we are well-positioned to deliver an easy ordering experience for providers with our representatives at the ready to provide the best-in-class white-glove service throughout the entire experience.”
According to data presented at The Liver Meeting 2021, the test has demonstrated superior sensitivity when compared to the existing blood-based tests for early liver cancer detection.
HelioLiver showed a sensitivity of 76% in early-stage HCC detection. The sensitivity of AFP, GALAD and ultrasound, other commonly used detection tools, was 57%, 65% and 47%, respectively.
In April, Helio Health and the National Cancer Center (NCC) were awarded a grant from the Ministry of Science and Technology of China to accelerate the development of the Helio Liver Test.